Skip to main content
SpringerLink
Log in

Melanoma

  • Chapter
Cancer Neurology in Clinical Practice

Abstract

Throughout the world, cases of melanoma are increasing at a rate of 5% per year (1). Over the last decade, the estimated lifetime risk of developing melanoma in the United States has increased from 1 in 105 to 1 in 75 (2,3). In the year 2000, an estimated 28,600 cases of in situ melanoma and 47,700 new cases of malignant melanoma were diagnosed in the United States (3). During that year, 7700 deaths were attributed to this disease. Overall, melanoma is the fifth most common cancer among men and the sixth most common cancer among women (3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Swerdlow Ai. International trends in cutaneous melanoma. Ann NY Acad Sci 1990; 60: 235–251.

    Article  Google Scholar 

  2. Khayat D, Coeffic D, Antoine E-C. Overview of medical treatments of metastatic malignant melanoma. Am Soc Clin Oncol 2000: 414–427.

    Google Scholar 

  3. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer Statistics, 2000. CA Cancer J Clin 2000; 50: 7–33.

    Article  CAS  PubMed  Google Scholar 

  4. Schuchter LM, Haluska F, Fraker D, Elenitsas R. In: Skin: Malignant Melanoma in Clinical Oncology. Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds., 2000, pp. 1318.

    Google Scholar 

  5. Pratt CB, Palmer MK, Thatcher N, Crowther D, Malignant melanoma in children and adolescents. Cancer 1981; 47: 392–397.

    Article  CAS  PubMed  Google Scholar 

  6. Davidoff AM, Cirrincone C, Seigler HF. Malignant melanoma in children. Ann Surg Oncol 1994; 1: 278–282.

    Article  CAS  PubMed  Google Scholar 

  7. Tate PS, Ronan SG, Feucht KA, Eng AM, Das Gupta TK. Melanoma in childhood and adolescence. Clinical and pathological features of 48 cases. J Pediatr Surg 1993; 28: 217–222.

    Article  CAS  PubMed  Google Scholar 

  8. Mehregan AH, Mehregan DA. Malignant melanoma in childhood. Cancer 1993; 71: 4096–4103.

    Article  CAS  PubMed  Google Scholar 

  9. Barnhill RL, Flotte TJ, Fleischli M, Perez-Atayde A. Cutaneous melanoma and atypical Spitz tumours in childhood. Cancer 1995; 76: 1833–1845.

    Article  CAS  PubMed  Google Scholar 

  10. Ceballos PI, Ruiz-Maldonado R, Mihm MC. Melanoma in children.’N Engl J Med 1995; 332: 656–662.

    Article  CAS  Google Scholar 

  11. Fleming ID, Cooper JS, Henson DE, et al. Malignant melanoma of the skin. In: AJCC Cancer Staging Handbook, 5th ed. Lippincott-Raven, Philadelphia, 1998, pp. 154–158.

    Google Scholar 

  12. Kuhn JA, McCarty TM. Malignant melanoma and the sentinel lymph node biopsy. Cancer Investig 1999; 17 (1): 39–46.

    CAS  Google Scholar 

  13. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193–201.

    CAS  PubMed  Google Scholar 

  14. Tomsu K, Van Eschen KB, Lee MA. Meta-analysis of median survival of patients with stage IV melanoma. Proc Am Soc Clin Onc. 1997; 16: 1784.

    Google Scholar 

  15. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Ang KK. Cutaneous melanoma. In: Cancer: Principles and Practice of Oncology, vol 2, 5th ed. DeVita VT Jr, Hellman S, Rosenberg SA, eds. Lippincott-Raven, Philadelphia, 1997, pp. 1947–1994.

    Google Scholar 

  16. Chang P, Knapper WH. Metastatic melanoma of unknown primary. Cancer 1982; 49: 1106–1111.

    Article  CAS  PubMed  Google Scholar 

  17. Das Gupta T, Bowden L, Berg JW. Malignant melanoma of unknown primary origin. Surg Gynec Obstet 1963; 117: 341–345.

    Google Scholar 

  18. Baab GH, McBride CM. Malignant melanoma: the patient with an unknown site of primary origin. Arch Surg 1975; 110: 896–900.

    Article  CAS  PubMed  Google Scholar 

  19. Milton GW, Shaw HM, McCarthy WH. Occult primary malignant melanoma: factors influencing survival. Br J Surg 1977; 64: 805–808.

    Article  CAS  PubMed  Google Scholar 

  20. Guiliano AE, Moseley HS, Morton DL. Clinical aspects of unknown primary melanoma. Ann Surg 1980; 191: 98–104.

    Article  Google Scholar 

  21. Reintgen DS, McCarty KS, Woodard B, Cox E, Seigler HF. Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet 1983; 156: 335–340.

    CAS  PubMed  Google Scholar 

  22. Huffman TA, Sterin WK. Ten-year survival with multiple metastatic malignant melanoma. Primary site unknown. Arch Surg 1973; 106: 234–235.

    Article  CAS  PubMed  Google Scholar 

  23. Balch CM, Houghton AN. Diagnosis of metastatic melanoma at distant sites. In: Cutaneous Melanoma. Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, eds. JB Lippincott, Philadelphia, 1992, pp. 439–467.

    Google Scholar 

  24. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000; 93: 9–18.

    Article  CAS  PubMed  Google Scholar 

  25. Sampson JH, Carter JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88: 11–20.

    Article  CAS  PubMed  Google Scholar 

  26. Wallace DC, Beardmore GL, Exton LA. Familial malignant melanoma. Ann Surg 1973; 177: 15–20.

    Article  CAS  PubMed  Google Scholar 

  27. Reimer RR, Clark WC, Greene MH, Ainsworth A, Fraumeni JF Jr. Precursor lesions in familial melanoma–a genetic preneoplastic syndrome. JAMA 1978; 239: 744–746.

    CAS  Google Scholar 

  28. Anderson DE, Smith JL, McBride CM. Hereditary aspects of malignant melanoma. JAMA 1967; 200: 741–746.

    Article  CAS  PubMed  Google Scholar 

  29. Duve S, Rakoski J. Cutaneous melanoma in patient with neurofibromatosis: a case report and review of the literature. Br J Dermatol 1994; 131: 290–294.

    Article  CAS  PubMed  Google Scholar 

  30. Greene MH, Fraumeni JF Jr. The hereditary variant of cutaneous malignant melanoma. In: Human Malignant Melanoma. Clark W, Goldman L, Mastrangelo M, eds. Grune and Stratton, New York, 1979, pp. 139–166.

    Google Scholar 

  31. Azizi E, Friedman J, Pavlotsky F, Iscovich J, Bornstein A, Shafir R, et al. Familial cutaneous malignant melanoma and tumors of the nervous system. Cancer 1995; 76: 1571–1578.

    Article  CAS  PubMed  Google Scholar 

  32. Bahuau M, Vidaud D, Jenkins RB, Bieche J, Kimmel DW, Assouline B, et al. Germ-line deletion involving the INK4 locul in familial proneness to melanoma and nervous system tumors. Cancer Res 1998; 58: 2298–2303.

    CAS  PubMed  Google Scholar 

  33. Nutt JG, Bird TD. Essential myoclonus in a kindred with familial malignant melanoma. Arch Neurol 1984; 41: 189–191.

    Article  CAS  PubMed  Google Scholar 

  34. Greene MH, Mead GD, Reimer RR, Bergfeld WF, Fraumeni JF Jr. Malignant melanoma and Charcot-Marie-Tooth disease. Am J Med Genet 1980; 5: 69–71.

    Article  CAS  PubMed  Google Scholar 

  35. Patchell RA. Brain metastases. Neurol Clin 1991; 9: 817–824.

    CAS  PubMed  Google Scholar 

  36. Hansen HH. Should initial treatment of small cell carcinoma include systemic chemotherapy and brain irradiation? Cancer Chemother Rep 1973;(Suppl 4 ): 239–241.

    Google Scholar 

  37. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. In: Neurological Epidemiology: Principles and Clinical Applications. Advances in Neurology, vol 19. Schoenberg BS, ed. Raven Press, New York, 1978, pp. 579–592.

    Google Scholar 

  38. Grant R, Whittle IR,Collie DA, Gregor A, Ironside JW. Referral pattern and management of patients with malignant brain tumours in south east Scotland. Health Bull 1996; 54 (3): 204–211.

    Google Scholar 

  39. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases histology, multiplicity, surgery, and survival. Cancer 1996; 78 (8): 1781–1788.

    Article  CAS  PubMed  Google Scholar 

  40. Patchell RA. Metastatic brain tumors. Neurol Clin 1995; 13 (4): 915–925.

    CAS  PubMed  Google Scholar 

  41. Moser RP. Surgery. In: Neuro-Oncology. Primary Tumors and Neurological Complications of Cancer. Twijnstra A, Keyser A, Ongerboer de Visser BW, eds. Elsevier, Amsterdam, 1993, p. 208.

    Google Scholar 

  42. Moon D, Maafs E, Peterson-Schaefer K, et al. A review of 567 cases of brain metastases from malignant melanoma. Melanoma Res 1993; 3: 40 (abstract).

    Article  Google Scholar 

  43. Baker AB. Metastatic tumors of the nervous system. Arch Pathol 1942; 34: 495–537.

    Google Scholar 

  44. McNeer G, Das Gupta T. Problem of recurrence in the management of melanoma. CA 1965; 15: 270–274.

    CAS  PubMed  Google Scholar 

  45. Stehlin JS Jr, Hills WJ, Rufine C. Disseminated melanoma biologic behavior and treatment. Arch Surg 1967; 94: 495–501.

    Article  PubMed  Google Scholar 

  46. Amer MH, Al-Sarraf M, Vaitkevicius VK. Clinical presentation, natural history and prognostic factors in advanced malignant melanoma. Surg Gynecol Obstet 1979; 149: 687–692.

    CAS  PubMed  Google Scholar 

  47. Atkinson L. Melanoma of the central nervous system. Aust N Z J Surg 1978; 48: 14–16.

    Article  CAS  PubMed  Google Scholar 

  48. Beresford HR. Melanoma of the central nervous system: treatment with corticosteroids and radiation. Neurology 1969; 19: 59–65.

    Article  CAS  PubMed  Google Scholar 

  49. Chason JL, Walker FB, Landers JW. Metastatic carcinoma in the central nervous system and dorsal root ganglia: a prospective autopsy study. Cancer 1963; 16: 781–787.

    Article  CAS  PubMed  Google Scholar 

  50. Badman DR, Camacho E, Wittes RE. The current causes of death in patients with malignant melanoma. Eur J Cancer 1978; 14: 327–330.

    Article  Google Scholar 

  51. Das Gupta T, Brasfield R. Metastatic melanoma. A clinico-pathological study. Cancer 1964; 17: 1323–1339.

    Article  Google Scholar 

  52. De la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases for malignant melanoma in humans. Cancer Res 1983; 43: 3427–3433.

    PubMed  Google Scholar 

  53. Einhorn LH, Burgess MA, Vallejos C, Bodey GP Sr, Gutterman J, Mavligit G, et al. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res 1974; 34 (8): 1995–2004.

    CAS  PubMed  Google Scholar 

  54. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978; 135: 807–810.

    Article  CAS  PubMed  Google Scholar 

  55. Brega K, Robinson WA, Winston K, Wittenberg W. Surgical treatment of brain metastases in malignant melanoma. Cancer 1990; 66: 2105–2110.

    Article  CAS  PubMed  Google Scholar 

  56. Fell DA, Leavens ME, McBride CM. Surgical versus nonsurgical management of metastatic melanoma of the brain. Neurosurgery 1980; 7: 238–242.

    Article  CAS  PubMed  Google Scholar 

  57. Hagen NA, Cirrincione C, Thaler HT, DeAngelis LM. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 1990; 40: 158–160.

    Article  CAS  PubMed  Google Scholar 

  58. Neuss M, Konig A, Herrmann HD. Intracranial melanoma metastases: surgical treatment and follow-up of 18 patients. Anticancer Res 1987; 7: 445–446.

    CAS  PubMed  Google Scholar 

  59. Overett TK, Shiu MH. Surgical treatment of distant metastatic melanoma. Indications and results. Cancer 1985; 56: 1222–1230.

    Article  CAS  PubMed  Google Scholar 

  60. Byrne TN, Cascino TL, Posner JB. Brain metastases from melanoma. J Neurooncol 1983; 1: 313–317.

    Article  CAS  PubMed  Google Scholar 

  61. Bullard DE, Cox EB, Seigler HF. Central nervous system metastases in malignant melanoma. Neurosurgery 1981; 8: 26–30.

    Article  CAS  PubMed  Google Scholar 

  62. Ginaldi S,Wallace S, Shalen P, et al. Cranial computed tomography of malignant melanoma (Stage IVA melanoma). AJR 1981; 136: 145–149.

    Google Scholar 

  63. Katz HR. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. Int J Radiat Oncol Bio! Phys 1981; 7: 907–911.

    Article  CAS  Google Scholar 

  64. Madajewicz S, Karokousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer 1984; 53: 2550–2552.

    Article  CAS  PubMed  Google Scholar 

  65. Mendez IM, Del Maestro RF. Cerebral metastases from malignant melanoma. Can J Neurol Sci 1988; 15: 119–123.

    CAS  PubMed  Google Scholar 

  66. Pennington DG, Milton GW. Cerebral metastasis from melanoma. Aust NZ J Surg 1975; 45: 405–409.

    Article  CAS  Google Scholar 

  67. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol 1978; 19: 579–592.

    CAS  PubMed  Google Scholar 

  68. Stevens G, Firth I, Coates A. Cerebral metastases from malignant melanoma. Radiother Oncol 1992; 23: 185–191.

    Article  CAS  PubMed  Google Scholar 

  69. Amer MH, Al-Sarraf M, Baker LH, et al. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment, and survival. Cancer 1978; 42: 660–668.

    Article  CAS  PubMed  Google Scholar 

  70. Shah JP, Huvos AG, Strong EW. Mucosal melanomas of the head and neck. Am J Surg 1977; 134: 531–535.

    Article  CAS  PubMed  Google Scholar 

  71. Takakura K, Sano K, Hojo S, Hirano A. Metastatic Tumors of the Central Nervous System. Igaku-Shoin, Ltd., New York, 1982.

    Google Scholar 

  72. Gottlieb JA, Frei E III, Luce JK. An evaluation of the management of patients with cerebral metastases from malignant melanoma. Cancer 1972; 29: 701–705.

    Article  CAS  PubMed  Google Scholar 

  73. Hayward RD. Malignant melanoma and the central nervous system. A guide for classification based on the clinical findings. J Neurol Neurosurg Psychiatry 1976; 39: 526–530.

    Article  Google Scholar 

  74. Retsas S, Gershuny AR. Central nervous system involvement in malignant melanoma. Cancer 1988; 61: 1926–1934.

    Article  CAS  PubMed  Google Scholar 

  75. Fernandez E, Maira G, Puca A, Vignati A. Multiple intracranial metastases of malignant melanoma with long-term survival. J Neurosurg 1984; 60: 621–624.

    Article  CAS  PubMed  Google Scholar 

  76. Bauman ML, Price TR. Intracranial metastatic malignant melanoma: long-term survival following subtotal resection. South J Med 1972; 65: 344–346.

    Article  CAS  Google Scholar 

  77. McCann KWP, Weir BKA, Elridge AR. Long-term survival after removal of metastatic malignant melanoma of the brain: Report of two cases. J Neurosurg 1968: 28: 483–487.

    Article  CAS  PubMed  Google Scholar 

  78. Lang EF, Slater J. Metastatic brain tumors: results of surgical and non-surgical treatment. Surg Clin N Am 1964; 44: 865–872.

    CAS  PubMed  Google Scholar 

  79. McNeel DP, Leavens ME. Long-term survival with recurrent metastatic intracranial melanoma: case report. J Neurosurg 1968; 29: 91–93.

    Article  CAS  PubMed  Google Scholar 

  80. Feun LG, Gutterman J, Burgess MA, Hersh EM, Mavligit G, McBride CM, et al. The natural history of resectable metastatic malanoma (Stage Iva melanoma). Cancer 1982; 50: 1656–1663.

    Article  CAS  PubMed  Google Scholar 

  81. Hena MA, Emrich LJ, Nambisan RN, Karakousis CP. Effect of surgical treatment on Stage IV melanoma. Am J Surg 1987; 153 (3): 270–275.

    Article  CAS  PubMed  Google Scholar 

  82. Wornom IL III, Smith JW, Soong SJ, McElvein R, Urist MM, Balch CM. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg 1986; 204 (2): 181–185.

    Article  PubMed  Google Scholar 

  83. Akslen LA, Hove LM, Hartveit F. Metastatic distribution in malignant melanoma. A 30-year autopsy study. Invas Metast 1987; 7: 253–263.

    CAS  Google Scholar 

  84. Choi KN, Withers HR, Rotman M. Metastatic melanoma of the brain. Rapid treatment or large dose fractions. Cancer 1985; 56: 10–15.

    Article  CAS  PubMed  Google Scholar 

  85. Branum GD, Seigler HF. Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am J Surg 1991; 162: 428–431.

    Article  CAS  PubMed  Google Scholar 

  86. Harpole DH Jr, Johnson CM, Wolfe WG, George SL, Seigler HF. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 1992;103(4):743–748; discussion 748–750.

    Google Scholar 

  87. Lejeune FJ, Lienard D, Sales F, Badr-el-Din H. Surgical management of distant melanoma metastases. Semin Surg Oncol 1992; 8: 381–391.

    Article  CAS  PubMed  Google Scholar 

  88. Roses DF, Karp NS, Oratz R, Dubin N, Harris MN, Speyer J, et al. Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet 1991; 172 (4): 262–268.

    CAS  PubMed  Google Scholar 

  89. Wong JH, Euhus DM, Morton DL. Surgical resection for metastatic melanoma to the lung. Arch Surg 1988; 123: 1091–1095.

    Article  CAS  PubMed  Google Scholar 

  90. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37 (4): 745–751.

    Article  CAS  PubMed  Google Scholar 

  91. Lagerwaard FJ, Levendag PC, Nowak PJCM, Eijkenboom WHM, Hanssens PEF, Schmitz PIM. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiation Oncology Biol Phys 1999; 43 (4): 795–803.

    Article  CAS  Google Scholar 

  92. Haar F, Patterson RH. Surgery for metastatic intracranial neoplasms. Cancer 1972; 30: 1241–1245.

    Article  CAS  PubMed  Google Scholar 

  93. Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol 1988; 45 (7): 741–744.

    Article  CAS  PubMed  Google Scholar 

  94. Enzmann DR, Kramer R, Norman D, Pollock J. Malignant melanoma metastatic to the central nervous system. Radiology 1978; 127 (1): 177–180.

    CAS  PubMed  Google Scholar 

  95. Beresford HR. Melanoma of the nervous system. Treatment with corticosteroids and radiation. Neurology 1969; 19 (1): 59–65.

    Article  CAS  PubMed  Google Scholar 

  96. Kuhn MJ, Hammer GM, Swenson LC, et al. MRI evaluation of “solitary” brain metastases with triple-dose gadoteridol: Compari-son with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patient. Comput Med Imaging Graph 1994; 18: 391–399.

    Google Scholar 

  97. Nomoto Y, Miyamoto T, Yamaguchi Y. Brain metastasis of small cell lung carcinoma: Comparison of Gd-DTPA enhanced magnetic resonance imaging and enhanced computerized tomography. Jpn J Clin Oncol 1994; 24: 258–262.

    CAS  PubMed  Google Scholar 

  98. Sze G, Milano E, Johnson C, Heier L. Detection of brain metastases: Comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. Am J Neuroradiol 1990; 11: 785–791.

    CAS  PubMed  Google Scholar 

  99. Kaye A. Malignant brain tumors. In: Reoperative Neurosurgery. Little J, Awad I, eds. Williams & Wilkins, Baltimore, pp. 49–76.

    Google Scholar 

  100. Scott M. Spontaneous intracerebral hematoma caused by cerebral neoplasms. Report of eight verified cases. J Neurosurg 1975; 42 (3): 338–342.

    Article  CAS  PubMed  Google Scholar 

  101. McCormik WF, Rosenfield DB. Massive brain hemorrhage: a review of 144 cases and examination of their causes. Stroke 1973; 4: 946–954.

    Article  Google Scholar 

  102. Somaza S, Kondziolka D, Lunsford JD, Kirkwood JM, Flichinger JC. Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg 1993; 79: 661–666.

    Article  CAS  PubMed  Google Scholar 

  103. Schold SC, Vurgin D, Golbey RB, Posner JB. Central nervous system metastases from germ cell carcinoma of testis. Sem Oncol 1979; 6: 102–108.

    CAS  Google Scholar 

  104. Dagi TF, Maccabe JJ. Metastatic trophoblastic disease presenting as a subarachnoid hermorrhage: Report of two cases and review of the literature. Surg Neurol 1980; 14 (3): 1975–1984.

    Google Scholar 

  105. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine 1985; 64 (1): 16–35.

    Article  CAS  PubMed  Google Scholar 

  106. Globus JH, Sapirstein M. Massive hemorrhage into brain tumors. JAMA 1942; 120: 348–352.

    Article  Google Scholar 

  107. Madow L, Alpers BJ. Cerebral vascular complications of metastatic carcinoma. J Neuropathol Exp Neurol 1952; 11: 137–148.

    Article  CAS  PubMed  Google Scholar 

  108. Strang RR, Ljungdahl TI. Carcinoma of the lung with a cerebral metastasis presenting as subarachnoid hemorrhage. Med J Aust 1962; 1: 90–91.

    Google Scholar 

  109. Mandybur TI. Intracranial hemorrhage caused by metastatic tumors. Neurology 1977; 27: 650–655.

    Article  CAS  PubMed  Google Scholar 

  110. Kondziolka D, Bernstein M, Resch L, Tator CH, Fleming JFR, Vanderlinden RG, Schutz H. Significance of hemorrhage into brain tumors: clinicopathological study. J Neurosurg 1987; 67: 852–857.

    Article  CAS  PubMed  Google Scholar 

  111. Little JR, Dial B, Belanger G, Carpenter S. Brain hemorrhage from intracranial tumor. Stroke 1979; 10 (3): 283–288.

    Article  CAS  PubMed  Google Scholar 

  112. Palmer FJ, Poulgrain AP. Metastatic melanoma simulating subdural hematoma. J Neurosurg 1978; 49: 301–302.

    Article  CAS  PubMed  Google Scholar 

  113. Bitoh S, Hasegawa H, Ohtsuki H, Obashi J, Fujiwara M, Sakurai M. Cerebral neoplasms initially presenting with massive intracerebral hemorrhage. Surg Neurol 1984; 22: 57–62.

    Article  CAS  PubMed  Google Scholar 

  114. Altas SW, Grossman RI, Gomori JM, Hackney DB, Goldberg HI, Zimmerman RA, Bilaniuk LT. Hemorrhagic intracranial malignant neoplasms: spin-echo MR imaging. Radiology 1987; 164 (1): 71–77.

    Google Scholar 

  115. Madonick MJ, Savitsky N. Subarachnoid hemorrhage in melanoma of the brain. Arch Neurol Psychiatry 1951; 65: 628–636.

    Article  CAS  Google Scholar 

  116. Wolpert SM, Zimmer A, Schechter MM, Zingesser LH: The neuroradiology of melanomas of the central nervous system. Am J Roentgenol Radium Ther Nucl Med 1967; 101 (1): 178–187.

    Article  CAS  PubMed  Google Scholar 

  117. Saha S, Meyer M, Krementz ET, Hoda S, Carter RD, Muchmore J, Sutherland C. Prognostic evaluation of intracranial metastasis in malignant melanoma. Ann Surg Oncol 1994; 1 (1): 38–44.

    Article  CAS  PubMed  Google Scholar 

  118. Mehta MP, Rozental JM, Levin AB, Mackie TR, Kubsad SS, Gehring MA, Kinsella TJ. Defining the role of radiosurgery in the management of brain metastases. Int J Radiat Oncol Biol Phys 1992; 24: 619–625.

    Article  CAS  PubMed  Google Scholar 

  119. Cooper JS, Carella R. Radiotherapy of intracerebral metastatic malignant melanoma. Radiology 1980; 134: 735–738.

    CAS  PubMed  Google Scholar 

  120. Stridsklev IC, Hagen S, Klepp O. Radiation therapy for brain metastases from malignant melanoma. Acta Radiol Oncol 1984; 23: 231–235.

    Article  CAS  PubMed  Google Scholar 

  121. Carella RJ, Gelber R, Hendrikson F, Berry HC, Cooper JS. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma. Cancer 1980; 45: 679–683.

    Article  CAS  PubMed  Google Scholar 

  122. Katz HR. The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. Int J Radiat Oncology Biol Phys 1981; 7: 897–906.

    Article  CAS  Google Scholar 

  123. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR. The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6 (1): 1–9.

    Article  CAS  PubMed  Google Scholar 

  124. Mandell L, Hilaris B, Sullivan M, Sundaresan N, Nori D, Kim JH, Martini N, Fuks Z. The treatment of single brain metastasis from non-oat cell lung carcinoma; surgery and radiation versus radiation alone. Cancer 1986; 58: 641–649.

    CAS  PubMed  Google Scholar 

  125. Patchell RA, Cirrincione C, Thaler HT, Galicich JH, Kim JH, Posner JB. Single brain metastases: surgery plus radiation or radiation alone. Neurology 1986; 36 (4): 447–453.

    Article  CAS  PubMed  Google Scholar 

  126. Bremer AM, West CR, Didolkar MS. An evaluation of the surgical management of melanoma of the brain. J Surg Oncol 1978; 10: 211–219.

    Article  CAS  PubMed  Google Scholar 

  127. Hafstrom L, Jansson PE, Stromblad LG. Intracranial metastases of malignant melanoma treated by surgery. Cancer 1980; 46: 2088–2090.

    Article  CAS  PubMed  Google Scholar 

  128. Hayward RD. Secondary malignant melanoma of the brain. Clin Oncol 1976; 2: 227–232.

    CAS  PubMed  Google Scholar 

  129. Oredsson S, Ingvarf C, Stromblad LG, Jonsson PE. Palliative surgery for brain metastases of malignant melanoma. EurJ Surg Oncol 1990; 16: 451–456.

    CAS  Google Scholar 

  130. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phy 1988; 15: 859–864.

    Article  CAS  Google Scholar 

  131. Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994; 29 (4): 711–717.

    Article  CAS  PubMed  Google Scholar 

  132. Egawa S, Tukiyama I, Akine Y, Kajiura Y, Yanagawa S, Watai K, Nomura K. Radiotherapy of brain metastases. Int J Radiat Oncol Biol Phys 1986; 12: 1621–1625.

    Article  CAS  PubMed  Google Scholar 

  133. Pladdet I, Boven E, Nauta J, Pinedo HM. Palliative care for brain metastases of solid tumour types. Neth J Med 1989; 34: 10–21.

    CAS  PubMed  Google Scholar 

  134. Zimm S, Wampler GL, Stablein D, HazraT, Young HF. Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer 1981; 48 (2): 384–395.

    Article  CAS  PubMed  Google Scholar 

  135. Flickinger JC, Kondziolka D, Lunsford LD, Coffey RJ, Goodman ML, Shaw EG, et al. A multi-institutional experience with stereo-tactic radiosurgery for solitary brain metastasis. Int J Radiation Oncology Biol Phy 1994;28(4):797–802. - -

    Google Scholar 

  136. Alexander E III, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995; 87 (1); 34–40.

    Article  PubMed  Google Scholar 

  137. Engenhart R, Kimmig BN, Hover KH, Wowra B, Romahn J, Lorenz WJ, van Kaick G, Wannemacher M. Long-term follow-up for brain metastases treated by percutaneous stereotactic single high-dose irradiation. Cancer 1993; 71: 1353–1361.

    Article  CAS  PubMed  Google Scholar 

  138. Shu H-KG, Sneed PK, Shiau C-Y, McDermott MW, Lamborn KE, Park E, et al. Factors influencing survival after gamma knife radio-surgery for brain metastases: Implications for development of treatment guidelines in patients with single and multiple lesions. Cancer J Sci Am 1996: 2 (6): 335.

    CAS  PubMed  Google Scholar 

  139. Seung SK, Shu HG, McDermott MW, Sneed PK, Larson DA. Stereotactic radiosurgery for malignant melanoma to the brain. Surg Clin North Am 1996; 76 (6): 1399–1411.

    Article  CAS  PubMed  Google Scholar 

  140. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffen T, Roth R. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981; 7: 1633–1638.

    Article  CAS  PubMed  Google Scholar 

  141. Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981: 7: 891–895.

    Article  CAS  PubMed  Google Scholar 

  142. DeAngelis L, Delattre J, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989; 39: 789–796.

    Article  CAS  PubMed  Google Scholar 

  143. Sundaresan N, Galicich J. Surgical treatment of brain metastases: clinical and computerized tomography evaluation of the results of treatment. Cancer 1985; 55: 1382–1388.

    Article  CAS  PubMed  Google Scholar 

  144. Lee Y, Naubert C, Glass P. Treatment related white matter changes in cancer patients. Cancer 1986; 57: 1473–1482.

    Article  CAS  PubMed  Google Scholar 

  145. Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg 1993; 79: 210–216.

    Article  CAS  PubMed  Google Scholar 

  146. Burt M, Wronski M, Arbit E, Galicich JH. Resection of brain metastases from non-small cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. J Thorac Cardiovasc Surg 1992;103:399–410; discussion 410–411.

    Google Scholar 

  147. Sawaya R, Bindal RK: Metastatic brain tumors. In: Brain Tumors. An Encyclopedic Approach. Kaye AH, Laws ER Jr, eds. Churchill Livingstone, Edinburgh, 1995, pp. 923–946.

    Google Scholar 

  148. Bindal RK, Sawaya R, Leavens ME, Hess KR, Taylor SH. Reoperation for recurrent metastatic brain tumors. J Neurosurg 1995; 83: 600–604.

    Article  CAS  PubMed  Google Scholar 

  149. Patchell RA, Tibbs PA, Walsh JW, Dempstey R, Maryuama Y, Krycio R, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494–500.

    Article  CAS  PubMed  Google Scholar 

  150. Constantini S, Lornowski R, Pomeranz S, Rappaport ZH. Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumours. Acta Neurochir (Wein) 1991; 109 (3–4): 93–97.

    Article  CAS  Google Scholar 

  151. Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996; 78: 1470–1476.

    Article  CAS  PubMed  Google Scholar 

  152. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993: 33: 583–590.

    Article  CAS  PubMed  Google Scholar 

  153. Adler JR, Cox RS, Kaplan I, Martin DP. Stereotactic radiosurgical treatment of brain metastases. J Neurosurg 1992; 76: 444–449.

    Article  CAS  PubMed  Google Scholar 

  154. Kihlstrom L, Karlsson B, Lindquist C. Gamma knife surgery for cerebral metastases. Implications for survival based on 16 years experience. Stereotact Funct Neurosurg 1993; 1: 45–50.

    Article  Google Scholar 

  155. Young RF, Vermeulen SS, Posewitz AE, Jacques DB, Copcutt B, Rand RW, et al. Gamma knife radiosurgery for treatment of multiple brain metastases. In: 2nd Congress of the International Stereotactic Radiosurgery Society, June 14–17, Boston, 1995, pp. 64–65.

    Google Scholar 

  156. Loeffler JS, Barker FG, Chapman PH. Role of radiosurgery in the management of central nervous system metastases. Cancer Chemother Pharmacol 1999; 43 (Suppl):S 11 - S14.

    Article  Google Scholar 

  157. Shiau C, Sneed PK, Shu HG, Lamborn KR, McDermott MW, Chang S, et al. Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiation Oncology Biol Phys 1997; 37 (2): 375–383.

    Article  CAS  Google Scholar 

  158. Grob JJ, Regis J, Laurans R, Delaunay M, Wolkenstein P, Paul K, et al. Management of solitary melanoma metastasis of the brain. Aust NZ J Surg 1989; 59: 321–324.

    Article  Google Scholar 

  159. Lavine SD, Petrovich Z, Cohen-Gadol AA, Masri LS, Morton DL, O’Day SJ, et al. Gamma knife radiosurgery for metastatic melanoma: analysis of survival, outcome, and complications. Neurosurgery 1999; 44: 59–64.

    Article  CAS  PubMed  Google Scholar 

  160. Rutigliano MJ, Lunsford LD, Kondziolka D, Strauss ML, Khanna V, Green M. The cost-effectiveness of stereotactic radiosurgery versus surgical resection inn the treatment of solitary metastatic brain tumors. Neurosurgery 1995; 37: 445–453.

    Article  CAS  PubMed  Google Scholar 

  161. Smalley SR, Laws ER, O’Fallon JR, Shaw EG, Schray MF. Resection for solitary brain metastases. J Neurosurg 1992; 77: 531–540.

    Article  CAS  PubMed  Google Scholar 

  162. Auchter RM, Lamond JP, Alexander E III, Buatti JM, Chappell R, Friedman WA, et al. A multi-institutional outcome and prognostic factor analysis of radiosurgery for respectable single brain metastasis. Int J Radiat Biol Phys 1996; 35: 27–35.

    Article  CAS  Google Scholar 

  163. Fuller BG, Kaplan ID, Adler J, Cox RS, Bagshaw MA. Stereotaxic radiosurgery for brain metastases: The importance of adjuvant whole brain irradiation. Int J Radiat Oncol Biol Phys 1992; 23: 413–418.

    Article  CAS  PubMed  Google Scholar 

  164. Loeffler JS, Flickinger JC, Shrieve DC. Radiosurgery for the treatment of intracranial lesions. In: Important Advances in Oncology. Devita VT, Hellman S, Rosenberg SA, eds. Lippincott, Philadelphia, pp. 141.

    Google Scholar 

  165. Greig NH. Chemotherapy of brain metastases: current status. Cancer Treatment Rev 1984; 11 (2): 157–186.

    Article  CAS  Google Scholar 

  166. Rosner D, Nemoto T, Pickren J, Lane W. Management of brain metastases from breast cancer by combination chemotherapy. J Neuroonco11983;1(2):131–137.

    Google Scholar 

  167. Cascino T, Byrne M, Deck H, Posner JB. Intra-arterial BCNU in the treatment of metastatic brain tumors. J Neurol Oncol 1983; 1: 211–218.

    Article  CAS  Google Scholar 

  168. Lange O, Scheef W, Haase K. Palliative radio-chemotherapy with ifosfamide and BCNU for breast cancer patients with cerebral metastases: a 5-year experience. Cancer Chemother Pharmacol 1990; 26 (Suppl): 78–80.

    Article  Google Scholar 

  169. Ushio Y, Arita N, Hayakawa T, Mogami H, Hasegawa H, Bitoh S, et al. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery 1991; 28 (2): 201–205.

    Article  CAS  PubMed  Google Scholar 

  170. Twelves C, Shouhami R, Harper P, et al. The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer 1990; 61: 147–50.

    Article  CAS  PubMed  Google Scholar 

  171. Comis RL. DTIC in malignant melanoma: a perspective. Cancer Treat Rep 1976; 60: 165–176.

    CAS  PubMed  Google Scholar 

  172. Lee SM, Betticher DC, Thatcher N. Melanoma: chemotherapy. Br Med Bull 1995; 51: 609–630.

    CAS  PubMed  Google Scholar 

  173. Kolaric K, Roth A, Jelicic I, Matkovic A. Phase II clinical trial of cis dichlorodiammine platinum (cis DDP) in metastatic brain tumors. J Cancer Res Clin Oncol 1982; 104: 287–293.

    Article  CAS  PubMed  Google Scholar 

  174. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, et al. Final report of the French multicenter phase II study of nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66 (9): 1873–1878.

    Article  CAS  PubMed  Google Scholar 

  175. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol 1997; 24 (1 Suppl 4): S39 - S43.

    CAS  PubMed  Google Scholar 

  176. Richards JM, Gale D, Mehta N, Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alpha for the treatment of metastatic melanoma. J Clin Oncol 1999; 17: 651–657.

    CAS  PubMed  Google Scholar 

  177. Middleton MR, Grob JJ, Aronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Onc 2000; 18: 158–166.

    CAS  Google Scholar 

  178. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Onc 1995; 13: 910–913.

    CAS  Google Scholar 

  179. Summers Y, Middleton MR, Calvert H, et al. Effect of temozolomide (TMZ) on central nervous system relapse in patients with advanced melanoma. 35th Annual Meeting of the American Society of Clinical Oncology, May 15–18, 1999. Abstract 2048.

    Google Scholar 

  180. Kersten MJ, Boogerd W, Batchelor D, et al. Combined immunotherapy with GM-CSF, IF-2 and IFN allows dose escalation of temozolomide and prevention of lymphocytopenia and brain metastases in metastatic malignant melanoma. 36th Annual Meeting of the American Society of Clinical Oncology, May 20–23, 2000. Abstract 2244.

    Google Scholar 

  181. Christodoulou C, Bafaloukos D, Kosmidos P, Papakostas P, Skarlos DV. Temozolomide (TMZ) in patients with brain metastases from solid tumors. A Hellenic Cooperative Group Study. 36th Annual Meeting of the American Society of Clinical Oncology, May 20–23, 2000. Abstract 665.

    Google Scholar 

  182. Abrey LE, Olson J, Boutros DY, et al. A phase II study of temozolomide for recurrent brain metastases. 5th Annual Meeting of the Society of Neuro-Oncology, November 9–12, 2000. Oral presentation.

    Google Scholar 

  183. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979; 29: 1369–1375.

    Article  CAS  PubMed  Google Scholar 

  184. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 1974; 30: 122–137.

    Article  CAS  PubMed  Google Scholar 

  185. Little JR, Dale AJ, Okazaki H. Meningeal carcinomatosis. Clinical manifestations. Arch Neurol 1974; 30: 138–143.

    Article  CAS  PubMed  Google Scholar 

  186. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49: 759–772.

    Article  CAS  PubMed  Google Scholar 

  187. Ehya H, Hajdu SI, Melamed MR. Cytopathology of nonlymphoreticular neoplasms metastatic to the central nervous system. Acta Cytol 1981; 25: 599–610.

    CAS  PubMed  Google Scholar 

  188. Amer MH, Al-Sarraf M, Baker L, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978; 42: 660–668.

    Article  CAS  PubMed  Google Scholar 

  189. Theodore WH, Gendelman S. Meningeal carcinomatosis. Arch Neurol 1981; 38: 696–699.

    Article  CAS  PubMed  Google Scholar 

  190. Twijnstra A, zan Zanten AP, Hart AA, Ongerboer de Visser BW. Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours. J Neurol Neurosurg Psychiatry 1987; 50 (3): 313–320.

    Article  CAS  PubMed  Google Scholar 

  191. Boogerd W, Hart AAM, Van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer. Cancer 1991; 67: 1685–1695.

    Article  CAS  PubMed  Google Scholar 

  192. Balm M, Hammack J. Leptomeningeal carcinomatosis: presenting features and prognostic factors. Arch Neurol 1996; 53: 626–632.

    Article  CAS  PubMed  Google Scholar 

  193. Wasserstrom WR, Schwartz MK, Fleisher M, Posner JB. Cerebrospinal fluid biochemical markers in central nervous system tumors: a review. Ann Clin Lab Sci 1981; 11: 239–251.

    CAS  PubMed  Google Scholar 

  194. Twijnstra A, Ongerboer de Visser BW, van Zanten AP. Diagnosis of leptomeningeal metastasis. Clin Neurol Neurosurg 1987; 89: 79–85.

    Article  CAS  PubMed  Google Scholar 

  195. Fleisher M, Wasserstrom WR, Schold SC, Schwartz MK, Posner JB. Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancer. Cancer 1981; 47: 2654–2659.

    Article  CAS  PubMed  Google Scholar 

  196. Van Zanten AP, Twijnstra A, Ongerboer de Visser BW, Hart AA, Nooyen WJ. Tumour markers in the cerebrospinal fluid of patients with central nervous system metastases from extracranial malignancies. Clin Chim Acta 1988; 175 (2): 157–166.

    Article  PubMed  Google Scholar 

  197. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999; 25: 103–119.

    Article  CAS  PubMed  Google Scholar 

  198. Krol G, Sze G, Malkin M, Walker R. MR of cranial and spinal meningeal carcinomatosis: comparison with CT and myelography. AJR 1988: 151; 583–588.

    Article  CAS  PubMed  Google Scholar 

  199. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990; 40: 85–89.

    Article  Google Scholar 

  200. Sze G, Soletsky S, Bronen E, Krol G. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. AJNR 1989; 10: 965–97.

    CAS  PubMed  Google Scholar 

  201. Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, et al. Diagnosis, management of, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995; 75: 2919–2931.

    Article  CAS  PubMed  Google Scholar 

  202. Grossman SA,Trump DL, Chen DCP, et al. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 1111ndium-DPTA ventriculography. Am J Med 1982; 73: 641–647.

    Google Scholar 

  203. Chamberlain MC, Corey-Bloom J. Leptomeningeal metastases: 111-Indium-DPTA CSF flow studies. Neurol 1991; 41: 1765–1769.

    Article  CAS  Google Scholar 

  204. Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: Diagnosis and treatment. Ann Neurol 1978; 3: 40–51.

    Article  CAS  PubMed  Google Scholar 

  205. Schiff D, O’Neill BP, Suman VJ. Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. Neurology 1997; 49: 452–456.

    Article  CAS  PubMed  Google Scholar 

  206. Schiff D, O’Neill BP. Intramedullary spinal cord metastases: clinical features and treatment outcome. Neurology 1996; 47: 906–912.

    Article  CAS  PubMed  Google Scholar 

  207. Strauss A, Dritschilo A, Nathanson L, Piro AJ. Radiation therapy of malignant melanomas: an evaluation of clinically used fractionation schemes. Cancer 1981; 47: 1262–1266.

    Article  CAS  PubMed  Google Scholar 

  208. Donaldson WF lII, Peppelmann WC, Yaw KM. Symptomatic malignant melanoma to the spine. J Spinal Disord 1993; 6: 360–363.

    Article  PubMed  Google Scholar 

  209. Helweg-Larson S. Clinical outcome in metastatic spinal cord compression: a prospective study of 153 patients. Acta Neurol Scand 1996; 94: 269–275.

    Article  Google Scholar 

  210. Kocialkowski A, Webb JK. Metastatic spinal tumors: Survival after surgery. Eur Spine J 1992; 1: 43–48.

    Article  CAS  PubMed  Google Scholar 

  211. Speigel DA, Sampson JH, Richardson WJ, Friedman AH, Rossitch E, Hardaker ST Jr, Seigler HF. Metastatic melanoma to the spine. Spine 1995; 20 (19): 2141–2146.

    Article  Google Scholar 

  212. Sorensen S, Borgesen SE, Rohde K, Rasmusson B, Bach F, Boge-Rasmussen T, Stjernholm P, Larsen BH, Agerlin N, Gjerris F, et al. Metastatic epidural spinal cord compression. Cancer 1990; 65 (7): 1502–1508.

    Article  CAS  PubMed  Google Scholar 

  213. Weigel B, Maghsudi M, Neumann C, Kretschmer R, Muller FJ, Nerlich M. Surgical management of symptomatic spinal metastases. Spine 1999; 24 (21): 2240–2246.

    Article  CAS  PubMed  Google Scholar 

  214. Schwechheimer K, Lemminger JM. Intramedullary metastases: report of 4 cases and review of the literature. Clin Neuropathol 1984; 4 (1): 28–37.

    Google Scholar 

  215. Dunne JW, Harper CG, Pamphlett R. Intramedullary spinal cord metastases: a clinical and pathological study of nine cases. QJM 1986; 61: 1003–1020.

    CAS  PubMed  Google Scholar 

  216. Grem JL, Burgess J, Trump DL. Clinical features and natural history of intramedullary spinal cord metastasis. Cancer 1985; 56: 2305–2314.

    Article  CAS  PubMed  Google Scholar 

  217. Carlson JA, Dickersin GR, Sober AF, Barnhill RL. Desmoplastic neurotropic melanoma; a clinicopathologic analysis of 28 cases. Cancer 1995; 75: 478–494.

    Article  CAS  PubMed  Google Scholar 

  218. Ogose A, Emura I, Iwabuchi Y, Hotta T, Inoue Y, Saito H. Malignant melanoma extending along the ulnar, median, and musculocutaneous nerves: a case report. J Hand Surg 1998; 23A: 875–878.

    Article  CAS  Google Scholar 

  219. Hufnagel T, Savino PJ, Zimmerman RA, Sergott RC. Painful ophthalmoplegia caused by neurotropic malignant melanoma. Can J Ophthalmol 1990; 25 (1): 38–41.

    CAS  PubMed  Google Scholar 

  220. Laskin WB, Weiss SW, Bratthauer GL. Epithelioid variant of malignant peripheral nerve sheath tumor (malignant epithelioid schwannoma). Am J Surg Pathol 1991; 15: 1136–1145.

    Article  CAS  PubMed  Google Scholar 

  221. King R, Busam K, Rosai J. Metastatic malignant melanoma resembling malignant peripheral nerve sheath tumor. Am J Surg Pathol 1999; 23 (12): 1499–1505.

    Article  CAS  PubMed  Google Scholar 

  222. Schadendorf D, Haas N, Ostmeier H, Kohlmus C, Gottschalk J, Algermissen B, et al. Amelanotic malignant melanoma presenting as malignant schwannoma. Br J Dermatol 1993; 129 (5): 609–614.

    Article  CAS  PubMed  Google Scholar 

  223. Sexton M, Maize JC. Malignant melanoma simulating schwannian differentiation. Am J Dermatopathol 1985; 7 (Suppl): 171–176.

    Article  PubMed  Google Scholar 

  224. Diaz-Cascajo C, Hoos A. Histopathologic features of malignant peripheral nerve sheath tumors are not restricted to metastatic malignant melanoma and can be found in primary malignant melanoma also. Am J Surg Pathol 2000; 24 (10): 1438–1439.

    Article  CAS  PubMed  Google Scholar 

  225. Enzinger FM, Weiss SW. Tumors of peripheral nerves. In: Soft Tissue Tumors, 3rd ed. Mosby, St Louis, 1995, pp. 889–928.

    Google Scholar 

  226. Iwamoto S, Odland PB, Piepkorn M, Bothwell M. Evidence that the p75 neurotrophin receptor mediates perineural spread of desmoplastic melanoma. J Am Acad Dermatol 1996; 35: 725–731.

    Article  CAS  PubMed  Google Scholar 

  227. Rakowicz-Szulczynska EM, Reddy U, Vorbrodt A, Herlyn D, Koprowski H. Chromatin and cell surface receptors mediate melanoma cell growth response to nerve growth factor. Mol Carcinog 1991; 4 (5): 388–396.

    Article  CAS  PubMed  Google Scholar 

  228. Boeck K, Hofmann S, Klopfer M, Ian U, Schmidt T, Tngst R, Thirkill CE, Ring J. Br J Dermatol 1997; 137 (3): 457–460.

    Article  CAS  PubMed  Google Scholar 

  229. Rush JA. Paraneoplastic retinopathy in malignant melanoma. Am J Ophthalmol 1993; 115 (3): 390–391.

    CAS  PubMed  Google Scholar 

  230. Potter MJ, Thirkill CE, Dam OM, Lee AS, Milam AH. Clinical and immunocytochemical findings in a case of melanoma-associated retinopathy. Ophthalmology 1999; 106 (11): 2121–2125.

    Article  CAS  PubMed  Google Scholar 

  231. Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol 1998; 106 (3): 307–311.

    Google Scholar 

  232. Weinstein JM, Kelman SE, Bresnick GH, Kornguth SE. Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology 1994: 101 (7): 1236–1243.

    CAS  PubMed  Google Scholar 

  233. Alexander KR, Fishman GA, Peachey NS, Marchese AL, Tso MO. `On’ response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci 1992: 33 (3): 477–483.

    CAS  PubMed  Google Scholar 

  234. Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 1993; 34 (1): 91–100.

    CAS  PubMed  Google Scholar 

  235. Remulla JF, Pineda R, Gaudio AR, Milam AH. Cutaneous melanoma-associated retinopathy with retinal periphlebits. Arch Ophthalmol 1995; 113 (7): 854–855.

    Article  CAS  PubMed  Google Scholar 

  236. Gittinger JW, Smith TW. Cutaneous melanoma-associated paraneoplastic retinopathy: histopathologic observations. Am J Ophthalmol 1999; 27 (5): 612–614.

    Article  Google Scholar 

  237. Singh AD, Milam AH, Shields CL, De Potter P, Shields JA. Melanoma-associated retinopathy. Am J Ophthalmol 1995; 119 (3): 369–370.

    CAS  PubMed  Google Scholar 

  238. Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 1992; 141: 881–886.

    CAS  PubMed  Google Scholar 

  239. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type I antineuronal nuclear autoantibodies. Neurology 1998; 50 (3): 652–657.

    Article  CAS  PubMed  Google Scholar 

  240. Antonine JC, Mosnier FJ, Lapras J, Convers P, Absi L, Laurent B, Michel D. Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. J Neurol Neurosurg Psychiatry 1996; 60 (2): 188–190.

    Article  Google Scholar 

  241. Bird SJ, Brown MJ, Shy ME, Scherer SS. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology 1996: 46 (3): 822–824.

    Article  CAS  PubMed  Google Scholar 

  242. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, et al. Phase I trial of the murine monoclonal anti-Gd2 antibody 14F2a in metastatic melanoma. Cancer Res 1992;52(16):43424347.

    Google Scholar 

  243. Fuller GN, Spies JM, Pollard JD, McLeod JG. Demyelinating neuropathies triggered by melanoma immunotherapy. Neurology 1994; 44: 2404–2405.

    Article  CAS  PubMed  Google Scholar 

  244. Yokoyama A, Kimura Y, Shigemura J. Psychiatric side effects of interferon. J Toxicol Sci 1996; 21: 93–96.

    Article  CAS  PubMed  Google Scholar 

  245. Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 1988; 6: 355–359.

    Article  CAS  PubMed  Google Scholar 

  246. Iivanainen M, Laaksonen R, Niemi ML, Farkkila M, Bergstrom L, Mattson K, et al. Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol Scand 1985; 72 (5): 475–480.

    Article  CAS  PubMed  Google Scholar 

  247. Muss HB, Richards F, Homesley HD, Spurr CL, Rudnick SA, Stuart JJ, et al. A phase I trial of recombinant leukocyte alpha 2 interferon in patients with advanced malignancy. Am J Clin Oncol 1985; 8 (2): 97–107.

    Article  CAS  PubMed  Google Scholar 

  248. Farkkila M, Iivanainen M, Roine R, Bergstrom L, Laaksonen R, Niemi ML, Cantell K. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 1984; 70: 42–46.

    Article  CAS  PubMed  Google Scholar 

  249. Muss HB, Kempf RA, Martino S, Rudnick SA, Greiner J, Cooper MR, et al. A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer. J Clin Oncol 1984; 2 (9): 1012–1016.

    CAS  PubMed  Google Scholar 

  250. Suter CC, Westmoreland BF, Sharbrough FW, Hermann RC. Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clin Proc 1984; 59: 847–850.

    Article  CAS  PubMed  Google Scholar 

  251. Honigsberger L, Fielding JW, Priestman TJ. Neurologic effects of recombinant human interferon (Letter). BMJ 1983; 286: 719.

    Article  CAS  PubMed  Google Scholar 

  252. Rohatiner AZ, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA. Central nervous system toxicity of interferon. Br J Cancer 1983: 47 (3): 419–422.

    Article  CAS  PubMed  Google Scholar 

  253. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-a therapy. Semin Oncol 1998(Suppl 1); 25: 39–47.

    Google Scholar 

  254. Bocci V. Central nervous system toxicity of interferons and other cytokines. J Biol Regul Homeos Agents 1988; 2: 107–118.

    CAS  Google Scholar 

  255. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-a. Neurology 1991; 41: 672–676.

    Article  CAS  PubMed  Google Scholar 

  256. Meyers CA, Obbens EAMT, Scheibel RS, Moser RP. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991; 68: 88–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. Denise M. Damek MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurology, University of Virginia Medical Center, Charlottesville, VA, USA

    David Schiff MD

  2. Center for Neuro-Oncology Dana-Farber Cancer Institute; and Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA

    Patrick Y. Wen MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Damek, D.M. (2003). Melanoma. In: Schiff, D., Wen, P.Y. (eds) Cancer Neurology in Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-317-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-317-0_23

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4703-4

  • Online ISBN: 978-1-59259-317-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation